ty -jour t1-间充质基质细胞输注调节稳定的COPD患者的全身免疫反应：A期试点研究JF-欧洲呼吸杂志JO -EUR RESSIR J DO -10.1183/13993003.02369-02369-2017- Armitage，Jesse au -Tan，Dino B.A.Au -Troedson，Russel au -Young，Paul Au -Lam，Kay -Vin au -Shaw，Kathryn au -Sturm，Marian Au -Weiss，Daniel J. Au -Moodley-穆多利，Yuben P. Y1-12-2018/03/01 UR-//www.qdcxjkg.com/content/51/3/3/1702369.Abstract N2-慢性阻塞性肺疾病（COPD）是全球发病率和死亡率的主要原因，这是由于持久性肺部和全身性炎症的治疗选择有限而导致的，该治疗选择有限表征这种情况[1]。最近，在COPD中，间充质基质细胞（MSC）的临床前研究表明，在系统性或气体内给药后减轻炎症和减少肺气肿的功效[2，3]。人类试验表明，在给COPD患者给药后，MSC并未改善肺活量法。然而，据报道，输注后1-3个月降低了C反应蛋白（CRP），是全身性炎症的标记。在这些试验中未对较早的时间点进行详细评估，这限制了对这些变化的进一步研究[4，5]。确定静脉注入的MSC的命运及其生物分布的潜在影响，以及先前试验中未探索的短期MSC诱导的全身变化，可以更好地描述MSC治疗的COPD.Meschymal骨化细胞输注的实用性。 an alternative immune-based therapeutic option for COPD patients http://ow.ly/5DpA30hQS6yThe authors thank study participants and staff at Cell and Tissue Therapies WA at Royal Perth Hospital for the preparation and handling of MSCs used in the study. The authors also acknowledge the use of facilities, and the scientific and technical assistance of the Australian Microscopy and Microanalysis Research Facility at the Centre for Microscopy, Characterisation and Analysis, University of Western Australia, a facility funded by the University, State and Commonwealth Governments. We also thank the Medical Research Foundation at Royal Perth Hospital for the use of their laboratory facilities throughout the study. This study was supported by funding from Therapeutics Innovation Australia (TIA) and a National Health and Medical Research Council grant. ER -